Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
OwnerJeremy Burrows, Anne Cooper +3inventors
InventorsJeremy Burrows, Anne Cooper, John Cumming, Thomas McInally, Howard Tucker
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I), compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
Claims16
A compound of formula (I):
- 64
- wherein:
- R1 is C1-6 alkyl, C3-7 cycloalkyl, C3-8 alkenyl or C3-8 alkynyl, each optionally substituted with one or more of:
- halo, hydroxy, cyano, nitro, C3-7 cycloalkyl, NR8R9, C(O)R10, NR13C(O)R14, C(O)NR17R18, NR19C(O)NR20R21, S(O)nR22, C1-6 alkoxy (itself optionally substituted by heterocyclyl or C(O)NR23R24), heterocyclyl, heterocyclyloxy, aryl, aryloxy, heteroaryl or heteroaryloxy;
- R2 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl(C1-4)alkyl, heteroaryl(C1-4)alkyl or heterocyclyl(C1-4)alkyl;
- R3 is C1-8 alkyl, C2-8 alkenyl, NR45R46, C2-8 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(C1-4)alkyl, heteroaryl(C1-4)alkyl or heterocyclyl(C1-4)alkyl;
- R46 is C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl(C1-4)alkyl, heteroaryl(C1-4)alkyl or heterocyclyl(C1-4)alkyl;
- wherein the groups of R2, R3 and R46, and the heterocyclyl, aryl and heteroaryl moieties of R1, are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, S(O)qR25, OC(O)NR26R27, NR28R29, NR30C(O)R31, NR32C(O)NR33R34, S(O)2NR35R36, NR37S(O)2R38, C(O)NR39R40, C(O)R41, CO2R42, NR43CO2R44, C1-6 alkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, phenyl, phenyl(C1-4)alkyl, phenoxy, phenylthio, phenyl(C1-4)alkoxy, heteroaryl, heteroaryl(C1-4)alkyl, heteroaryloxy or heteroaryl(C1-4)alkoxy;
- wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(O)kC1-4 alkyl, S(O)2NH2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3;
- the C3-7 cycloalkyl, aryl, heteroaryl and heterocyclyl moieties of R1, R2 and R3 being additionally optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6 alkoxy(C1-6)alkyl;
- R4, R5, R6 and R7 are, independently, hydrogen, C1-6 alkyl {optionally substituted by halo, cyano, hydroxy, C1-4 alkoxy, OCF3, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2, NHC(O)(C1-4 alkyl), N(C1-4 alkyl)C(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), N(C1-4 alkyl)S(O)2(C1-4 alkyl), CO2(C1-4 alkyl), C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, C(O)NH2, CO2H, S(O)2(C1-4 alkyl), S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, heterocyclyl or C(O)(heterocyclyl)}, S(O)2NH2, S(O)2NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, C(O)(C1-4 alkyl), CO2H, CO2(C1-4 alkyl) or C(O)(heterocyclyl);
- or two of R4, R5, R6 and R7 can join to form, together with the ring to which they are attached, a bicyclic ring system;
- or two of R4, R5, R6 and R7 can form an endocyclic bond (thereby resulting in an unsaturated ring system);
- X is C(O), S(O)2, C(O)C(O), a direct bond or C(O)C(O)NR47;
- k, m, n, p and q are, independently, 0, 1 or 2;
- R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43 and R44 are, independently, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl each or which is optionally substituted by halo, cyano, nitro, hydroxy, C1-4 alkyl, C4 alkoxy, SCH3, S(O)CH3, S(O)2CH3, NH2, NHCH3, N(CH3)2, NHC(O)NH2, C(O)NH2, NHC(O)CH3, S(O)2N(CH3)2, S(O)2NHCH3, CF3, CHF2, CH2F, CH2CF3 or OCF3;
- and R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43 and R44 may additionally be hydrogen;
- R8, R9, R10, R13, R14, R17, R18, R19, R20, R21, R23, R24, R45 and R47 are, independently, hydrogen, alkyl {optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, heterocyclyl or phenyl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy)}, phenyl (itself optionally substituted by halo, hydroxy, nitro, S(O)kC1-4 alkyl, S(O)2NH2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3) or heteroaryl (itself optionally substituted by halo, hydroxy, nitro, S(O)kC1-4 alkyl, S(O)2NH2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3);
- R22 is alkyl {optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, heterocyclyl or phenyl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy)}, phenyl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy) or heteroaryl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy);
- the pairs of substituents:
- R8 and R9, R13 and R14, R17 and R18, R20 and R21, R23 and R24, R26 and R27, R28 and R29, R30 and R31, R32 with either R33 or R34, R33 and R34, R35 and R36, R37 and R38, R39 and R40 and R43 and R44 may, independently, join to form a ring and such a ring may also comprise an oxygen, sulphur or nitrogen atom;
- where for any of the foregoing heterocyclic groups having a ring —N(H)— moiety, that —N(H)— moiety may be optionally substituted by C1-4 alkyl (itself optionally substituted by hydroxy), C(O)(C1-4 alkyl), C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2 or S(O)2(C1-4 alkyl);
- a ring nitrogen and/or sulphur atom is optionally oxidised to form an N-oxide and/or an S-oxide;
- foregoing heteroaryl or heterocyclyl rings are C- or, where possible, N-linked;
- or a pharmaceutically acceptable salt thereof or a solvate thereof.
A compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof, for use as a medicament.
A compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in therapy.
A compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in modulating CCR5 receptor activity in a warm blooded animal.
Dependencies are inferred from the claim text.